RAPT Therapeutics has been granted a patent for crystalline forms of a C-C chemokine receptor type 4 (CCR4) antagonist, along with oral dosage forms and methods of preparation and use. The patent includes Compound 2-((R)-3-(1-(1-((R)-1-(2,4-Dichlorophenyl)ethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-13]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol benzene sulfonate in crystalline form. GlobalData’s report on RAPT Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on RAPT Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. RAPT Therapeutics's grant share as of May 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline form of ccr4 antagonist compound
A recently granted patent (Publication Number: US12006318B2) discloses a crystalline compound, 2-((R)-3-(1-(1-((R)-1-(2,4-Dichlorophenyl)ethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-13]pyrazin-6-yl)azetidin-3-yl)piperidin-1-yl)ethan-1-ol benzene sulfonate, with specific absorption peaks in an X-ray powder diffractogram using Cu Ka radiation. The compound exhibits characteristic absorption peaks at various angles, a melting point range, and specific X-ray powder diffractogram patterns, as detailed in the patent claims.
Moreover, the patent also covers pharmaceutical compositions containing the crystalline compound in combination with a pharmaceutically acceptable vehicle. These compositions, particularly in oral tablet dosage form, are intended for the treatment of immune-, inflammatory-, or cancer-related diseases or disorders. The patent further outlines methods for administering the crystalline compound or pharmaceutical compositions to patients in need of such treatment, targeting a wide range of conditions from allergic disorders to various types of cancers. Additionally, co-administration with other therapeutic agents, such as pembrolizumab, is also disclosed as part of the treatment methods outlined in the patent.
To know more about GlobalData’s detailed insights on RAPT Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
